Sector News

In regional shakeup, Novartis’ Alcon fires two Asia execs

June 12, 2015
Life sciences
Two key executives of Novartis subsidiary Alcon with responsibility for Asia were fired this week, AsianScientist reported, after confirming the action by the parent company.
 
Roy Acosta, Asia & Russia region president, and Jim West, Asia & Russia chief financial officer, of global medical company Alcon were fired on June 10, AsianScientist said, noting that Novartis declined to discuss the reasons for the move.
 
In an email response, Novartis confirmed to FiercePharmaAsia that the two executives had left the company.
 
“Novartis can confirm that Roy Acosta, Region President, Asia & Russia, and Jim West, Chief Financial Officer, Asia & Russia, will be leaving the company after 25 years of service, respectively,” a company spokesman said in an email.
 
Eric Van Oppens, who is currently head of the Asia cluster for Novartis Pharma, will replace Acosta as Asia & Russia region president at Alcon, effective July 1, the spokesperson said.
 
Oppens, who is currently head of the Asia Cluster for Novartis Pharma, has been appointed as region president, Asia & Russia at Alcon, effective July 1.
 
Acosta reported directly to Jeff George, head of Alcon and member of the executive committee of Swiss-based Novartis.
 
Alcon, which makes sterile eye care products and operates out of Fort Worth, Texas, is the second-largest division of Novartis; it was bought in 2011 for $51.9 billion.
 
AsianScientist said that Acosta joined Alcon in 1989 and has held various leadership positions within U.S. and International Operations, citing his biography on the company’s website.
 
Alcon faced accusations in 2013 of diverting funds meant for postmarketing surveys to bribe doctors in China.
 
Novartis faced sales sanctions and investigations by regulators last year in Japan over failure to report serious side effects during clinical trials as well as complaints that sales officials had an indirect role in managing data.
 
AsianScientist said a spokesperson for Novartis Media Relations in Basel confirmed that Acosta and West were let go on Wednesday.
 
By EJ Lane
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).